Talquetamab, cevostamab and CAR-T in the future treatment of myeloma

Описание к видео Talquetamab, cevostamab and CAR-T in the future treatment of myeloma

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, Birmingham, AL, outlines how the latest drug therapies can be integrated into the treatment algorithm for multiple myeloma. Dr Costa also explains the excitement surrounding chimeric antigen receptor (CAR) T-cell therapies, such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and bispecific antibodies, such as talquetamab and cevostamab, for the treatment of myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Комментарии

Информация по комментариям в разработке

Похожие видео